<DOC>
	<DOCNO>NCT02108951</DOCNO>
	<brief_summary>The purpose Australian study ass efficacy safety nilotinib 300mg twice daily patient chronic myeloid leukemia chronic phase intolerant responsive 1st line treatment imatinib dasatinib . Eligible patient previously treat imatinib dasatinib least 3 month experience non-hematologic toxicity whilst document response meet PBS authority 1st line treatment CML without current MR4.5 .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Nilotinib 300mg Twice Daily Patients With Philadelphia Positive Chronic Myeloid Leukaemia ( CML ) Chronic Phase Who Are Intolerant Prior Tyrosine Kinase Inhibitors .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Eastern Cooperative Oncology Grou ( ECOG ) Performance Status 0 , 1 , 2 . 2 . Patient diagnosis Ph+ CMLCP associate BCRABL quantifiable RQPCR ( IS ) . 3 . Patient receive minimum 3 month imatinib dasatinib treatment ( dose ) since initial diagnosis document response . 4 . Patient eligible Pharmaceutical Benefits Scheme ( PBS ) reimburse 1st line TKI treatment . 5 . Patient experience nonhematological Adverse Events ( AE ( ) ) grade , persist least 1 month despite supportive care recur grade least . Patients , Investigator 's discretion , require immediate discontinuation due severity adverse event also eligible . 6 . No current plan antileukemia therapy . 7 . Adequate organ function . 8 . Potassium , Magnesium Total Calcium Lower limit normal . 1 . Prior treatment nilotinib . 2 . Prior Accelerated Phase ( AP ) , Blast Crisis ( BC ) allogeneictransplant ( unless patient receive autologous transplant Chrionic Phase ( CP ) prior transplant never AP BC ) . 3 . Patient document Molecular Response ( MR ) 4.5 time study entry 4 . Patients atypical BCRABL transcript quantifiable standard RQPCR . 5 . Known impaired cardiac function . 6 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug . 7 . Pregnant breast feeding ( lactate ) woman . 8 . Women childbearing potential unwilling unable use highly effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>CML</keyword>
	<keyword>Ph-CML</keyword>
	<keyword>leukaemia</keyword>
	<keyword>leukemia</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>chronic myeloid leukaemia</keyword>
	<keyword>TKI intolerance</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>tyrosine kinase inhibitor intolerance</keyword>
</DOC>